Proteomics diagnostic tests shift from lab coats to commercial launch

{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-04-28T07:02:57Z","datePublished":"2026-04-28T07:02:57Z","description":"Proteomics International is rolling out a commercial roadmap with a four-test diagnostics suite targeting kidney disease, cancer and endometriosis across Australia and the US.","headline":"Proteomics diagnostic tests shift from lab coats to commercial launch","keywords":"Bulls N' Bears, Shares, Sharemarket","author":[{"@type":"Person","name":"Doug Bright"}],"mainEntityOfPage":{"@id":"https://www.smh.com.au/business/companies/proteomics-diagnostic-tests-shift-from-lab-coats-to-commercial-launch-20260428-p5zrtr.html","@type":"WebPage"},"image":{"@type":"ImageObject","height":"1322.6666666666665","url":"https://static.ffx.io/images/$zoom_1%2C$multiply_0.7025%2C$ratio_1.777778%2C$width_1059%2C$x_249%2C$y_363/t_crop_custom/q_86%2Cf_auto/43511c8375f2d8d53086eaa727e6eaa7e6ea3b7c80f3ccea270d8bea45cbf32b","width":"744"},"isAccessibleForFree":false,"hasPart":[{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".paywall"}],"publisher":{"@type":"NewsMediaOrganization","name":"The Sydney Morning Herald","logo":{"@type":"ImageObject","height":"628","url":"https://www.smh.com.au/metro-assets/assets/static/smh.png","width":"1200"},"url":"https://www.smh.com.au"},"isPartOf":{"@type":["CreativeWork","Product"],"name":"The Sydney Morning Herald","productID":"smh.com.au:webonly"}}{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","item":{"@id":"https://www.smh.com.au/business","name":"Business"},"position":1},{"@type":"ListItem","item":{"@id":"https://www.smh.com.au/business/companies","name":"Companies"},"position":2},{"@type":"ListItem","item":{"@id":"https://www.smh.com.au/topic/bulls-n'-bears-san","name":"Bulls N' Bears"},"position":3}]}AdvertisementSponsoredBusinessCompaniesBulls N' BearsProteomics diagnostic tests shift from lab coats to commercial launchBrought to you by BULLS N’ BEARSDoug BrightApril 28, 2026 — 5:02pmSaveYou have reached your maximum number of saved items.Remove items from your saved list to add more.ShareAAAProteomics International Laboratories has drawn a line under its long research phase and is now marching toward what every listed biotech eventually needs - commercial traction.In a fresh strategic presentation released this week under the guidance of its new managing director and chief executive officer, David Morris, the Perth-based company outlined a disciplined three-year plan to convert its proteomics science platform into a scalable diagnostics business, with clear priorities around sales growth, reimbursement pathways and operational efficiency.Proteomics International Laboratories has an evolving portfolio of diagnostic techniques that identify proteins found in people with targeted clinical conditions.For smaller life sciences players, that transition can be the toughest hurdle. Great science does not always translate into revenue. Proteomics appears well aware of the challenge and has chosen a capital-light route, leaning on distribution partners rather than on expensive in-house sales infrastructure.Management says its distributor model should enable earlier acceptance and adoption, lower establishment risk and better capital efficiency than devoting time and effort on running direct or hybrid sales channels.AdvertisementThe company’s portfolio currently centres on four tests. Leading the charge is PromarkerD,…

This excerpt is published under fair use for community discussion. Read the full article at The Sydney Morning Herald.